eShowcase: Oracle Initiatives Focus on Drug Safety
Recent announcements streamline adverse event reporting
Recent announcements streamline adverse event reporting
Oracle (Redwood Shores, CA) announced Safety in a Capsule, an IT and service collaboration between Oracle, Tata Consultancy Services (TCS), and DrugLogic. The offering combines Oracle's Siebel Contact Center Integration Pack for Oracle's Adverse Event Reporting (AER) System, DrugLogic's signal detection solution QScan, and TCS' Knowledge Process Outsourcing services to monitor and analyze pre- and postmarketing AER data for increased drug safety.
The Siebel Contact Center Integration Pack for the Oracle AER passes customer, product complaint, and potential AER information from the contact center to automatically load event-related information into the Oracle AER system. This solution works to reduce duplicate data entry, conflict resolution, and reconciliation. It is part of the Oracle Application Integration Architecture.
Oracle, (800) 672-2531, www.oracle.com
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
